
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp is poised for growth with anticipated revenue acceleration starting in 2026, supported by ongoing international expansion and a disciplined approach to investment in revenue-generating activities. The company has reaffirmed a strong gross margin target of 74% for 2025 while tightening operating expense expectations, suggesting effective cost management. Future value prospects are closely tied to successful clinical trials and the integration of AI-driven technologies, which are expected to enhance patient identification and facilitate broader market adoption of its innovative treatments for severe emphysema.
Bears say
Pulmonx Corp reported preliminary Q3 revenue of approximately $21.5 million, reflecting a sequential decline from Q2's revenue of $23.9 million, highlighting a concerning slowdown in revenue generation. This decline prompted a revision of the company's annual revenue guidance to a range of $90 million to $92 million, indicating a loss of momentum that may further increase execution risks associated with its product models. Additionally, the company's gross margins fell from 72% in Q2 due to pressures from product mix and conversion timing, which raises further concerns about overall profitability moving forward.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares